Results 191 to 200 of about 465,609 (241)
The median hazard ratio: a useful measure of variance and general contextual effects in multilevel survival analysis. [PDF]
Stat Med, 2017 Austin PC, Wagner P, Merlo J.
europepmc +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives Acute kidney injury (AKI) is a common but often underrecognized complication in ischemic stroke patients undergoing mechanical thrombectomy, particularly among those with pre‐existing renal impairment. This study evaluated the incidence, risk factors, and clinical impact of AKI in this high‐risk population.
Michał Borończyk +10 more
wiley +1 more source
Quantifying the average of the time-varying hazard ratio via a class of transformations. [PDF]
Lifetime Data Anal, 2015 Chen Q +5 more
europepmc +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Use of Cross-Sectional Imaging Body Composition Assessment to Predict Pancreas Transplant Outcomes
Transplant InternationalColin Snook +8 more
doaj +1 more source
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. [PDF]
J Clin Oncol, 2014 Uno H +15 more
europepmc +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao +5 more
wiley +1 more source
Cumulative Hazard Ratio Estimation for Treatment Regimes in Sequentially Randomized Clinical Trials. [PDF]
Stat Biosci, 2015 Tang X, Wahed AS.
europepmc +1 more source
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket +14 more
wiley +1 more source
The Randomised Clinical Trial and the Hazard Ratio - medical research's Emperor's New Clothes? [PDF]
BMC Cancer, 2014 Stephens R, Stewart D.
europepmc +1 more source